EMEA-000170-PIP02-10-M03
Key facts
| Invented name |
Revolade
|
| Active substance |
Eltrombopag
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0070/2019
|
| PIP number |
EMEA-000170-PIP02-10-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of secondary thrombocytopenia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|